Stammdaten
Unternehmen
| Name | Amylyx Pharmaceuticals, Inc. |
|---|---|
| Ticker | AMLX |
| CIK | 0001658551 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Amylyx Pharmaceuticals, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 12:13:37.017249 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -6,461 | 14.58 | -94,205.26 | -105,5% | |
| 2026-03-02 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -7,909 | 14.52 | -114,851.33 | -128,6% | |
| 2026-02-02 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -3,557 | 14.65 | -52,096.89 | -58,3% | |
| 2026-01-06 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -3,326 | 11.11 | -36,953.86 | -41,4% | |
| 2025-12-01 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -6,580 | 14.35 | -94,418.39 | -105,7% | |
| 2025-09-30 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -12,039 | 14.58 | -175,517.78 | -196,6% | |
| 2025-09-30 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -10,558 | 14.65 | -154,650.42 | -173,2% | |
| 2025-03-31 | FRATES JAMES M | Officer, Chief Financial Officer | Open Market Sale | -10,896 | 3.47 | -37,805.85 | -42,3% | |
| 2025-03-31 | Bedrosian Camille L | Officer, Chief Medical Officer | Open Market Sale | -12,425 | 3.47 | -43,082.45 | -48,3% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.